BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer. 1986

S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase II trial of Baker's antifol in metastatic sarcoma.
November 1977, Cancer treatment reports,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase II study of Baker's antifol in advanced colorectal cancer.
April 1978, Cancer treatment reports,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.
March 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.
February 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
July 2006, Cancer biology & therapy,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
July 2008, Cancer chemotherapy and pharmacology,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
December 2015, Investigational new drugs,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
August 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
December 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Krasnow, and M Green, and D J Perry, and M A Eisenberger, and A Johnston-Early, and F Muggia, and M H Cohen
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
December 2012, Oral oncology,
Copied contents to your clipboard!